# A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease

> **NCT04721366** · — · COMPLETED · sponsor: **Takeda** · enrollment: 11 (actual)

## Conditions studied

- Gaucher Disease

## Interventions

- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04721366
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-08
- **Primary completion:** 2023-04-17
- **Final completion:** 2023-04-17
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04721366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04721366, "A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04721366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*